journal
https://read.qxmd.com/read/38625619/comorbidity-profiling-identifies-potential-subtype-of-elderly-patients-with-nasopharyngeal-carcinoma
#1
JOURNAL ARTICLE
Ying Li, Yuhui Pan, Zongwei Huang, Lishui Wu, Wenxi Wu, Siqi Xu, Zihan Chen, Xin Chen, Jun Lu, Sufang Qiu
BACKGROUND: Few studies have assessed the comprehensive associations among comorbid diseases in elderly patients with nasopharyngeal carcinoma (NPC). This study sought to identify potential comorbidity patterns and explore the relationship of comorbidity patterns with the mortality risk in elderly patients with NPC. METHODS: A total of 452 elderly patients with NPC were enrolled in the study. The network analysis and latent class analysis were applied to mine comorbidity patterns...
April 16, 2024: Oncologist
https://read.qxmd.com/read/38597608/a-process-to-reanalyze-clinical-dna-sequencing-data-for-biomarker-matching-in-the-lung-map-master-protocol
#2
JOURNAL ARTICLE
Joel W Neal, Katherine Minichiello, Ryan Brennick, Richard S P Huang, Matthew C Hiemenz, Cornel Amler, Jyoti Patel, Roy Herbst, Karen L Reckamp, Hossein Borghaei, Louise Highleyman, Mary W Redman, Lincoln W Pasquina, David E Kozono
For cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 patients (98...
April 10, 2024: Oncologist
https://read.qxmd.com/read/38581718/clinical-outcomes-of-etoposide-and-cytarabine-as-consolidation-in-elderly-patients-with-primary-cns-lymphoma
#3
JOURNAL ARTICLE
Yu Ri Kim, Hyunsoo Cho, Soo-Jeong Kim, Haerim Chung, Hye Won Kook, Ji Eun Jang, June-Won Cheong, Jin Seok Kim
BACKGROUND: A consolidation strategy has not been established for transplant-ineligible elderly patients with primary central nervous system lymphoma (PCNSL). In this study, we aimed to retrospectively evaluate the clinical outcomes of etoposide and cytarabine (EA) as consolidation chemotherapy for transplant-ineligible patients with PCNSL following high-dose methotrexate (MTX)-based induction chemotherapy. MATERIALS AND METHODS: Between 2015 and 2021, newly diagnosed transplant-ineligible patients with PCNSL with diffuse large B-cell lymphoma were consecutively enrolled...
April 6, 2024: Oncologist
https://read.qxmd.com/read/38581687/tumor-response-predicts-survival-time-of-nivolumab-monotherapy-for-advanced-gastric-cancer-a-subgroup-analysis-of-the-deliver-trial-jaccro-gc-08
#4
JOURNAL ARTICLE
Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, Masashi Fujii
BACKGROUND: This prospective observational study evaluated the real-world effectiveness of nivolumab monotherapy in previously treated advanced gastric cancer (GC). A preplanned 2-year final analysis was performed to confirm survival and tumor behavior with nivolumab monotherapy. PATIENTS AND METHODS: The primary endpoint was overall survival (OS). The data regarding tumor size were prospectively collected and evaluated using the RECIST criteria. Exploratory analyses were performed for survival according to the tumor response and depth of response (DpR) in patients with measurable lesions who were receiving nivolumab monotherapy as third- or later-line therapy...
April 6, 2024: Oncologist
https://read.qxmd.com/read/38574190/optimal-sequential-strategies-for-antibody-drug-conjugate-in-metastatic-breast-cancer-evaluating-efficacy-and-cross-resistance
#5
JOURNAL ARTICLE
Meiting Chen, Riqing Huang, Rishang Chen, Fei Pan, Xiujiao Shen, Haifeng Li, Qixiang Rong, Xin An, Cong Xue, Yanxia Shi
BACKGROUND: The optimal sequential strategy for antibody-drug conjugates (ADCs) in breast cancer remains uncertain. This study aimed to evaluate the efficacy and potential resistance of second ADC (ADC2) following the first ADC (ADC1) in human epidermal growth factor receptor 2 (HER2)-positive and HER2-low MBC. METHODS: This retrospective, multicenter, real-world study enrolled patients with MBC who received at least 2 different types of ADCs in 3 hospitals in China between July 1, 2017 and May 1, 2023...
April 4, 2024: Oncologist
https://read.qxmd.com/read/38564263/factors-influencing-adherence-to-the-risk-management-program-for-women-with-a-genetic-predisposition-to-breast-cancer-real-world-data-from-a-french-multicenter-program
#6
JOURNAL ARTICLE
Ke Zhou, Martine Bellanger, Louise Crivelli, Sandy Laham, Charlotte Huet, Caroline Abadie
BACKGROUND: Risk management programs targeting women with genetic predispositions to breast cancer (BC), eg, BRCA1 and BRCA2, are effective assuming full adherence with the program protocol. However, high risk to BC in women and equal access to care may not result in high and uniform adherence with the program. OBJECTIVE: To elucidate factors influencing adherence with screening program in women with genetic predispositions to BC. MATERIAL AND METHODS: We retrieved data from a multicenter pathogenic-related BC surveillance program across 4 French regions...
April 2, 2024: Oncologist
https://read.qxmd.com/read/38558248/are-dna-repair-gene-alterations-associated-with-the-response-to-platinum-based-regimen-and-immune-checkpoint-inhibitors-in-patients-with-solid-tumors
#7
JOURNAL ARTICLE
Clément Chabot, Antoine Italiano, Amandine Crombé, Isabelle Soubeyran, Yech'an Laizet, Emmanuel Khalifa, Sophie Cousin
We analyzed the antitumor activity of platinum-based chemotherapies and then immune checkpoint inhibitors (ICI) in all-comers patients with solid tumors having a somatic DNA damage repair gene alteration (DDR-GA) identified through a prospective precision medicine study (NCT02534649). Each DDR-GA was classified as pathogenic (Pa), probably pathogenic (PPa), and unknown pathogenicity (UPa) according to OncoKB and ClinVAR databases. Between January 2018 and May 2020, 662 patients were screened. One hundred ninety-nine tumors with DDR-GA were found in 121 (18...
April 1, 2024: Oncologist
https://read.qxmd.com/read/38558247/early-incorporation-to-palliative-care-epc-in-patients-with-advanced-non-small-cell-lung-cancer-the-paco-randomized-clinical-trial
#8
JOURNAL ARTICLE
Silvia Allende, Jenny G Turcott, Emma Verástegui, Oscar Rodríguez-Mayoral, Diana Flores-Estrada, Dana Aline Pérez Camargo, Maritza Ramos-Ramírez, Jorge-Negueb Martínez-Hernández, Luis F Oñate-Ocaña, Pamela Soberanis Pina, Andrés F Cardona, Oscar Arrieta
BACKGROUND: Patients with non-small cell lung cancer (NSCLC) experience a considerable disease burden, evident in symptomatic and psychological spheres. Advanced cancer represents a complex scenario for patients and the healthcare team. Early palliative care (EPC) has been proven as a clinically meaningful strategy in this context by several randomized trials but not in a resource-limited setting. This study aimed to evaluate the effect of EPC compared with standard oncological care (SOC) in patients with metastatic NSCLC in Mexico...
April 1, 2024: Oncologist
https://read.qxmd.com/read/38557816/storage-disposal-and-use-of-opioids-among-cancer-patients-in-central-china-a-multi-center-cross-sectional-study
#9
JOURNAL ARTICLE
Mi Zhang, Huili Chen, Chenxi Luo, Xuanxuan Wang, Liang Liu, Dongfang Wu, Hong Cheng
OBJECTIVE: Unsafe opioid-related practices can lead to abuse, diversion, and accidental overdoses. In this study, we aimed to describe the patterns and beliefs regarding the storage, disposal, and use of opioids among Chinese patients with cancer in their home settings, which remain unclear. METHODS: A multicenter cross-sectional survey was conducted in Hubei Province from October 2022 to June 2023. We collected information on the storage, disposal, and use of opioids among cancer pain inpatients in the oncology department...
April 1, 2024: Oncologist
https://read.qxmd.com/read/38547052/five-year-follow-up-of-polaris-01-phase-ii-trial-toripalimab-as-salvage-monotherapy-in-chinese-patients-with-advanced-melanoma
#10
JOURNAL ARTICLE
Bixia Tang, Rong Duan, Xiaoshi Zhang, Shuikui Qin, Di Wu, Jing Chen, Hong Yao, Zhihong Chi, Jun Guo, Xieqiao Yan
BACKGROUND: To investigate the efficacy and toxicity after long-term follow-up of anti-PD-1 antibody in advanced melanoma with predominantly acral and mucosal subtypes. METHODS AND PATIENTS: In the POLARIS-01 phase II trial, 128 Chinese patients with advanced melanoma refractory to standard therapy received toripalimab until disease progression or unacceptable toxicity for ≤2 years. For those who progressed after discontinuation due to 2-year treatment completion, rechallenge was allowed...
March 28, 2024: Oncologist
https://read.qxmd.com/read/38537665/comparison-of-the-response-to-neoadjuvant-therapy-between-immunohistochemistry-her2-3-and-her2-2-ish-early-stage-breast-cancer-a-retrospective-multicenter-cohort-study
#11
JOURNAL ARTICLE
Dechuang Jiao, Guangyu Li, Hao Dai, Jia Wang, Jiao Zhang, Yangyang Hou, Xuhui Guo, Yajie Zhao, Xilong Gong, Zhenzhen Liu
BACKGROUND: According to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria, both immunohistochemical HER2 (3+) and HER2 (2+)/in situ hybridization (ISH) amplified [HER2 (2+)/ISH+] breast cancers (BCs) fall under the HER2-positive BC category. However, there is a lack of studies exploring the difference of neoadjuvant therapeutic response between patients with HER2 (3+) and HER2 (2+)/ISH+ early BC. We aimed to evaluate the neoadjuvant therapeutic response, long-term outcome, and intrinsic subtype heterogeneity between HER2 (3+) and HER2 (2+)/ISH+ BC...
March 27, 2024: Oncologist
https://read.qxmd.com/read/38531814/correction-to-comparing-drug-shortages-experienced-by-institutions-with-national-metrics
#12
(no author information available yet)
No abstract text is available yet for this article.
March 26, 2024: Oncologist
https://read.qxmd.com/read/38530254/concurrent-atezolizumab-plus-bevacizumab-and-high-dose-external-beam-radiotherapy-for-highly-advanced-hepatocellular-carcinoma
#13
JOURNAL ARTICLE
Chung-Wei Su, Wei Teng, Eric Yi-Liang Shen, Bing-Shen Huang, Po-Ting Lin, Ming-Mo Hou, Tsung-Han Wu, Din-Li Tsan, Chia-Hsun Hsieh, Ching-Ting Wang, Pei-Mei Chai, Chun-Yen Lin, Shi-Ming Lin, Chen-Chun Lin
BACKGROUND: Atezolizumab plus bevacizumab (atezo-bev) has been recommended for advanced hepatocellular carcinoma (HCC). High-dose external beam radiotherapy (RT) is recognized for its excellent local tumor control. The efficacy and safety of concurrent atezo-bev with RT for highly advanced HCC has been minimally explored. METHODS: In this preliminary retrospective study, we assessed patients with highly advanced HCC, characterized by Vp4 portal vein thrombosis or tumors exceeding 50% of liver volume, who received concurrent atezo-bev and RT (group A)...
March 26, 2024: Oncologist
https://read.qxmd.com/read/38529688/combination-of-egfr-tki-and-chemotherapy-versus-egfr-tki-monotherapy-as-neoadjuvant-treatment-of-stage-iii-n2-egfr-mutant-non-small-cell-lung-cancer
#14
JOURNAL ARTICLE
Yingqi Xu, Hao Ji, Yidan Zhang, Liwen Xiong, Baohui Han, Hua Zhong, Jianlin Xu, Runbo Zhong
BACKGROUND: The efficacy of neoadjuvant treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy in patients with stage III-N2 EGFR-mutant remains unsatisfactory. This study explored the potential benefits of combining first-generation EGFR-TKI with chemotherapy as a neoadjuvant treatment for patients with stage III-N2 EGFR-mutant non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The medical records of patients with III-N2 EGFR-mutant NSCLC who received neoadjuvant therapy with EGFR-TKI at Shanghai Chest Hospital from October 2011 to October 2022 were retrospectively reviewed...
March 25, 2024: Oncologist
https://read.qxmd.com/read/38527096/real-world-evaluation-of-primary-versus-secondary-prevention-of-skeletal-related-events-in-metastatic-castration-resistant-prostate-cancer
#15
JOURNAL ARTICLE
William J Phillips, Fred Saad, Jennifer Leigh, Alborz Jooya, Colleen Webber, Scott Morgan, Robert MacRae, Jean-Marc Bourque, Peter Tanuseputro, Michael Ong
INTRODUCTION: Anti-osteoclast treatment with denosumab or zoledronate is known to effectively reduce the need for radiotherapy to bone and other skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC). In this study, we analyze primary versus secondary initiation of bone-targeting agents (BTAs) relative to first palliative bone radiotherapy in patients dying of mCRPC. METHODS: Provincial administrative databases from Ontario, Canada identified patients with prostate cancer (2007-2018, n = 98 646) who received continuous androgen deprivation therapy (n = 29 453), died of prostate cancer (2013-2018, n = 3864), and received life-prolonging therapy for mCRPC (n = 1850)...
March 25, 2024: Oncologist
https://read.qxmd.com/read/38527005/ocular-effects-of-mek-inhibitor-therapy-literature-review-clinical-presentation-and-best-practices-for-mitigation
#16
JOURNAL ARTICLE
Karen W Jeng-Miller, Miles A Miller, Jeffrey S Heier
MEK signaling pathway targeting has emerged as a valuable addition to the options available for the treatment of advanced cancers including melanoma and non-small cell lung cancer. Ophthalmologic monitoring of patients taking part in clinical trials of MEK inhibitors has shown that while ocular effects are common, generally emerging during the first days to weeks of treatment, the majority are either asymptomatic or have minimal visual impact and are benign, resolving without intervention or the need to reduce or stop MEK inhibitor therapy...
March 25, 2024: Oncologist
https://read.qxmd.com/read/38520745/osimertinib-in-patients-with-treatment-naive-egfr-mutant-non-small-cell-lung-cancer-overall-survival-post-progression-management-and-budget-impact-analysis-in-real-world
#17
JOURNAL ARTICLE
Giulia Pasello, Martina Lorenzi, Daniela Scattolin, Alessandro Del Conte, Fabiana Cecere, Alberto Pavan, Marianna Macerelli, Valentina Polo, Sara Pilotto, Mariacarmela Santarpia, Enrico Cumerlato, Valentina Da Ros, Giada Targato, Alberto Bortolami, Laura Bonanno, Alessandra Ferro, Alessandro Dal Maso, Stefano Frega, Valentina Guarneri
INTRODUCTION: The observational multicenter prospective FLOWER study (NCT04965701) confirmed effectiveness and safety of osimertinib in the real-world (RW) management of untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) patients. METHODS: Herein, we report updated survival data, post-progression management, cost/effectiveness and budget impact (BI) of osimertinib compared with a RW population receiving gefitinib or erlotinib. RESULTS: Overall, 189 Caucasian patients receiving first-line osimertinib were included...
March 23, 2024: Oncologist
https://read.qxmd.com/read/38520743/single-cell-sequencing-illuminates-thymic-development-an-updated-framework-for-understanding-thymic-epithelial-tumors
#18
JOURNAL ARTICLE
Christopher S Nabel, Jeanne B Ackman, Yin P Hung, Abner Louissaint, Gregory J Riely
Thymic epithelial tumors (TETs) are rare tumors for which treatment options are limited. The ongoing need for improved systemic therapies reflects a limited understanding of tumor biology as well as the normal thymus. The essential role of the thymus in adaptive immunity is largely effected by its epithelial compartment, which directs thymocyte (T-cell) differentiation and immunologic self-tolerance. With aging, the thymus undergoes involution whereby epithelial tissue is replaced by adipose and other connective tissue, decreasing immature T-cell production...
March 23, 2024: Oncologist
https://read.qxmd.com/read/38520742/cancers-of-unknown-primary-origin-real-world-clinical-outcomes-and-genomic-analysis-at-the-european-institute-of-oncology
#19
JOURNAL ARTICLE
Luca Boscolo Bielo, Carmen Belli, Edoardo Crimini, Matteo Repetto, Liliana Ascione, Gloria Pellizzari, Celeste Santoro, Valeria Fuorivia, Massimo Barberis, Nicola Fusco, Elena Guerini Rocco, Giuseppe Curigliano
BACKGROUND: Cancer of unknown primary origin (CUP) poses a significant challenge due to poor clinical outcomes and limited treatment options. As such, further definition of clinicopathological factors and genomic profile to better adapt treatment strategies is required. METHODS: Medical records were interrogated to retrospectively include CUP with available clinical and genomics data at the European Institute of Oncology. Next-generation sequencing (NGS) included targeted panels...
March 23, 2024: Oncologist
https://read.qxmd.com/read/38518107/anticancer-drugs-related-hypogonadism-in-male-patients-with-advanced-cancers-on-active-treatment-a-systematic-review
#20
JOURNAL ARTICLE
Giacomo Massa, Luca Zambelli, Ernesto Zecca, Morena Shkodra, Gabriele Tinè, Augusto Caraceni
BACKGROUND: In male patients with cancer treated with antineoplastic drug, hypogonadism is a neglected cause of diminished quality of life. This condition may be cancer related as well as toxicity related. The role of antineoplastic drug in causing hypogonadism is poorly understood. The aim of this systematic review was to establish the prevalence, nature (primary/secondary), and impact of hypogonadism on quality of life in male patients with cancer on antineoplastic therapy. METHODS: The search strategy used PubMed, Embase, and Cochrane databases to select articles in English language that described hypogonadism in male patients with cancer...
March 22, 2024: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.